Stay informed with the latest updates for the inheritable blood disorders community.

Medical Advisory
Medical Advisory
Medical Advisory #419: Voluntary Recall Issued for 2 Lots of Kogenate FS
Medical Advisory
Medical Advisory
Medical Advisory #420: Voluntary Recall Issued for 2 Lots of Helixate FS
Medical
FDA Approves HCV Combination Therapy for all Major Genotypes
FDA Approves HCV Combination Therapy for all Major Genotypes
Medical Advisory
Medical Advisory
Medical Advisory #418: Koate DVI Shipments on Hold
Medical
HTRS Extends Pre-Proposal Deadline for Research Awards
HTRS Extends Pre-Proposal Deadline for Research Awards
NBDF & Community
NHF-McMaster University Clinical Practice Guideline – Care Models for Hemophilia Management Released
NHF-McMaster University Clinical Practice…
NBDF & Community
NHF Statement Regarding PLOS Medicine Article
NHF Statement Regarding PLOS Medicine Article
Industry
BioMarin Reports Continued Progress in Clinical Trial for Hemophilia A Gene Therapy
Spark Announces New Data on Its FIX Gene Therapy
Industry
UniQure Escalates Hemophilia B Gene Therapy Manufacturing Site
UniQure’s Gene Therapy Performing well in Hemophilia B Trial
Medical
FDA Accepts License Application and Grants Priority Review for Emicizumab
FDA Approves CSL’s AFSTYLA® for Hemophilia A
Industry
Shire/Baxalta Complete $32 Billion Merger
Shire/Baxalta Complete $32 Billion Merger
Medical
Bayer Responds to NHF-HFA Letter
New MASAC Document Addresses Clotting Factor Concentrate Supply in the…
Industry
ACE910 Shows Positive Efficacy and Safety Data in Phase I Trial
ACE910 Shows Positive Efficacy and Safety Data in Phase I Trial
Medical
SIPPET Study Results Published in NEJM
SIPPET Study Results Published in NEJM
NBDF & Community
NHF Receives 4-Star Rating from Charity Navigator
NHF Receives 4-Star Rating from Charity Navigator